Show Summary Details
Page of

Combined endocrine and chemotherapy in breast cancer 

Combined endocrine and chemotherapy in breast cancer
Chapter:
Combined endocrine and chemotherapy in breast cancer
Author(s):

Ishmael Jaiyesimi

, Shannon Wills

, Richard Zekman

, Dave Decker

, and Aman U. Buzdar

DOI:
10.1093/med/9780199218141.003.0007
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 02 June 2020

Combining adjuvant endocrine therapy with tamoxifen, and chemotherapy is superior than either modality alone.

Sequentially administered antiestrogen therapy is better than concomitant administration with chemotherapy.

Efficacy of aromatase inhibitors is not altered by prior adjuvant chemotherapy.

The role of ovarian ablation or suppression in premenopausal women following adjuvant chemotherapy remains an area of ongoing research.

In metastatic disease, endocrine therapies and chemotherapies should be sequentially utilized - concomitant use offers no advantage.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.